Incidence and Recurrence of Melanoma Are Equivalent
the Cancer Therapy Advisor take:
Findings presented at the American Academy of Dermatology summer meeting showed a similar rate of diagnosis of in situ or invasive melanoma compared with the long-term risk of invasive melanoma recurrence.
A diagnosis of invasive melanoma compared with a diagnosis of in situ melanoma had an increased risk of invasive recurrence within 2 years of diagnosis. After that 2 year window, the risk of invasive recurrence was equivalent to the risk of diagnosis of either disease.
As a result, the follow-up for patients with in situ melanoma or invasive melanoma should be identical. The 40-year retrospective study used data from the Surveillance, Epidemiology, and End Results (SEER) program for 1973 to 2011.
Investigators identified 55,661 patients with a diagnosis of in situ melanoma, 97,614 patients with locally invasive melanoma, and 14,999 patients with regional or distant invasive melanoma. Those with a diagnosis of in situ melanoma had a hazard of invasive recurrence of 1.0, while the localized group and the regional/distant group had a hazard ratio of 1.03 and 1.08, respectively.
Diagnosis of in situ or invasive conferred a similar long-term risk of invasive melanoma recurrence.
Thereafter, the risk of invasive recurrence remains the same, regardless of the initial diagnosis, Hyemin Pomerantz, MD, of Brown University in Providence, R.I., reported here at the American Academy of Dermatology summer meeting.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia
- Exercise and Cancer
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer